Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S0QY
|
|||
| Former ID |
DIB021095
|
|||
| Drug Name |
TUG-770
|
|||
| Synonyms |
TUG770
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C19H14FNO2
|
|||
| Canonical SMILES |
C1=CC=C(C(=C1)CC#N)C#CC2=CC(=C(C=C2)CCC(=O)O)F
|
|||
| InChI |
1S/C19H14FNO2/c20-18-13-14(6-8-17(18)9-10-19(22)23)5-7-15-3-1-2-4-16(15)11-12-21/h1-4,6,8,13H,9-11H2,(H,22,23)
|
|||
| InChIKey |
KIZUBVPJNPVIIN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1402601-82-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Free fatty acid receptor 1 (GPR40) | Target Info | Agonist | [2] |
| KEGG Pathway | Insulin secretion | |||
| Reactome | G alpha (q) signalling events | |||
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Incretin Synthesis, Secretion, and Inactivation | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6483). | |||
| REF 2 | Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Med Chem Lett. 2013 May 9;4(5):441-445. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.